primary liver cancer
Conditions
Interventions
Experimental group:5 mg dexamethasone, 5 mg tropisetron,
Control group:5 mg tropisetron
Sponsors
Changhai Hospital, Navy Military Medical University, Shanghai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. According to the imaging techniques and / or biopsy guidelines of the code for diagnosis and treatment of primary liver cancer (2019 Edition), unresectable HCC was diagnosed; 2. They are not able to accept palliative surgery or radiotherapy, have at least one measurable lesion, and are willing to accept TACE treatment; 3. There was no history of using hormone preparation in the first 3 months; 4. Barcelona stage: bclc-b or C; 5. Child Pugh a5-b7; 6. Aged 18 to 75 years; 7. In the first week, ECoG score was 0-1; 8. Good organ and bone marrow function (1) Hemoglobin >= 9.0g/dl; (2) White blood cell count >= 3.0 x 10^9/ µ L; (3) Platelet count >= 75 x 10^9/ µ L; (4) Total bilirubin = 2.8g/dl; (7) International normalized ratio (INR) = 30ml / min. 9. Life expectancy exceeds 12 weeks; 10. They voluntarily accepted the treatment of the study protocol and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Combined with heart, brain, kidney, lung and other organ diseases; 2. The formation of main portal vein tumor thrombus, bile duct tumor thrombus and collateral vessels was less; 3. Severe varices of gastric fundus and esophagocardia, severe portal hypertension, with the risk of rupture and bleeding; 4. Systemic infection, sepsis and liver abscess; 5. Patients with severe liver cirrhosis caused by abnormal liver function, or with obvious ascites, jaundice; 6. Tumors accounted for 70% or more of the whole liver; 7. Allergic constitution, or allergic to the drugs involved in this study. 8. The patients who did not use drugs according to the regulations after informed consent could not judge the curative effect, or the information was incomplete, which affected the curative effect judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of embolism syndrome; | — |
Countries
China
Contacts
Public ContactMeng Yongbin
Changhai Hospital, Navy Military Medical University, Shanghai
Outcome results
None listed